- Home
- WERN vs HRMY Comparison
WERN vs HRMY Comparison
Compare WERN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WERN
- HRMY
- Stock Information
- Founded
- WERN 1956
- HRMY 2017
- Country
- WERN United States
- HRMY United States
- Employees
- WERN N/A
- HRMY N/A
- Industry
- WERN Trucking Freight/Courier Services
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- WERN Industrials
- HRMY Health Care
- Exchange
- WERN Nasdaq
- HRMY Nasdaq
- Market Cap
- WERN 1.7B
- HRMY 1.8B
- IPO Year
- WERN N/A
- HRMY 2020
- Fundamental
- Price
- WERN $29.33
- HRMY $37.52
- Analyst Decision
- WERN Hold
- HRMY Strong Buy
- Analyst Count
- WERN 14
- HRMY 9
- Target Price
- WERN $31.00
- HRMY $55.33
- AVG Volume (30 Days)
- WERN 784.1K
- HRMY 620.1K
- Earning Date
- WERN 07-29-2025
- HRMY 08-05-2025
- Dividend Yield
- WERN 1.91%
- HRMY N/A
- EPS Growth
- WERN N/A
- HRMY 13.13
- EPS
- WERN 0.29
- HRMY 2.62
- Revenue
- WERN $2,973,292,000.00
- HRMY $744,852,000.00
- Revenue This Year
- WERN $0.29
- HRMY $20.33
- Revenue Next Year
- WERN $5.89
- HRMY $17.67
- P/E Ratio
- WERN $102.10
- HRMY $14.21
- Revenue Growth
- WERN N/A
- HRMY 20.62
- 52 Week Low
- WERN $23.02
- HRMY $26.47
- 52 Week High
- WERN $42.48
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- WERN 59.14
- HRMY 69.24
- Support Level
- WERN $28.44
- HRMY $35.04
- Resistance Level
- WERN $28.95
- HRMY $37.27
- Average True Range (ATR)
- WERN 0.78
- HRMY 1.14
- MACD
- WERN 0.01
- HRMY 0.37
- Stochastic Oscillator
- WERN 60.74
- HRMY 98.59
About WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.